-
1 Comment
Eurofins-Cerep SA is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
Based on the above factors, Eurofins-Cerep SA gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Diagnostics & Research |
| Exchange | PA |
| CurrencyCode | EUR |
| ISIN | FR0013256518 |
| Dividend Yield | 0.0% |
|---|---|
| Beta | 0.49 |
| PE Ratio | 14.35 |
| Target Price | 1.7 |
| Market Cap | 132M |
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALECR.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
